{"id":1016491,"date":"2026-11-02T21:03:27","date_gmt":"2026-11-03T02:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-upcoming-november-investor-conferences\/"},"modified":"2026-11-02T21:03:27","modified_gmt":"2026-11-03T02:03:27","slug":"dbv-technologies-to-participate-in-upcoming-november-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-upcoming-november-investor-conferences\/","title":{"rendered":"DBV Technologies to Participate in Upcoming November Investor Conferences"},"content":{"rendered":"
\n

Ch\u00e2tillon, France, November 2, 2026<\/p>\n

\n DBV Technologies to Participate in Upcoming November Investor Conferences<\/b>\n <\/p>\n

DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT) (the \u201cCompany\u201d), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in November:<\/p>\n

\n Guggenheim Securities 3rd Annual Healthcare Innovation Conference \u2013 November 9, 2026<\/b>
\n
Format:\u00a0Fireside Chat
Time:\u00a0\u00a08:00 am ET
Location:\u00a0Boston, MA<\/p>\n

\n 2026 LifeSci Growth & Innovation Summit \u2013 November 16, 2026<\/b>
\n
Format:\u00a01 on 1 Meetings
Location:\u00a0London, UK<\/p>\n

A live webcast of the fireside chat will be available on the Events section of the Company’s website here<\/a>.<\/p>\n

Replays will also be available on DBV Technologies\u2019 website for 90 days after the event.<\/p>\n

\n About DBV Technologies<\/b>
\n
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN\u00ae Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN\u00ae Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual\u2019s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin\u2019s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company\u2019s food allergy programs include ongoing clinical trials of VIASKIN\u00ae Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.<\/p>\n

DBV Technologies is headquartered in Ch\u00e2tillon, France, with North American operations in Warren, NJ. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company\u2019s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT \u2013 CUSIP: 23306J309).<\/p>\n

For more information, please visit www.dbv-technologies.com<\/a> and engage with us on X (formerly Twitter)<\/a> and LinkedIn<\/a>.<\/p>\n

VIASKIN is a registered trademark of DBV Technologies.<\/p>\n

\n Investor Contact <\/b>
\n
Virginie Boucinha
DBV Technologies
virginie.boucinha@dbv-technologies.com<\/a><\/p>\n

\n Media Contact<\/b>
\n
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com<\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n